New methods to detect nerve damage from chemotherapy
Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy
This study is looking at a new way to see and measure nerve damage in the skin caused by chemotherapy, which can help doctors better understand and manage the symptoms for cancer patients dealing with nerve pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11121422 on NIH RePORTER |
What this research studies
This research aims to develop non-invasive microscopic techniques to identify and quantify nerve damage caused by chemotherapy, known as chemotherapy-induced peripheral neuropathy (CIPN). Using a technology called portable confocal microscopy, the study will visualize changes in nerve endings in the skin of cancer patients. By assessing the density of specific nerve structures, researchers hope to create a reliable tool for evaluating CIPN, which can lead to better management of symptoms during and after cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing chemotherapy who are experiencing symptoms of peripheral neuropathy.
Not a fit: Patients who are not receiving chemotherapy or those without symptoms of peripheral neuropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a standardized method for early detection and monitoring of nerve damage in cancer patients, potentially improving their treatment outcomes.
How similar studies have performed: Preliminary studies using similar imaging techniques have shown promising results in detecting nerve damage in cancer patients, indicating potential for success in this research.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Kang, Dongkyun — University of Arizona
- Study coordinator: Kang, Dongkyun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.